US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PagerDuty, Inc.

15.56

-1.4300-8.42%

Post-market: 15.11-0.4500-2.89%19:57 EDT

Volume:2.51M

Turnover:39.53M

Market Cap:1.42B

PE:-26.29

High:16.59

Open:16.48

Low:15.37

Close:16.99

Loading ...

Overview Company News Filings

PagerDuty Report Finds A Majority of CIOs and CTOs View Agentic AI as Core to Future IT Operations

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

3 Reasons PD is Risky and 1 Stock to Buy Instead

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

PagerDuty (PD) Upgraded to Strong Buy: What Does It Mean for the Stock?

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Arbutus Provides 2025 Corporate and Financial Update

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

PagerDuty to Present at the 27th Annual Needham Growth Conference

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

Press Release: Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PD/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":15.56,"timestamp":1743796800000,"preClose":16.99,"halted":0,"volume":2508253,"hourTrading":{"tag":"盘后","latestPrice":15.11,"preClose":15.56,"latestTime":"19:57 EDT","volume":6142,"amount":95208.1,"timestamp":1743811048583},"delay":0,"floatShares":81906729,"shares":91084454,"eps":-0.591956,"marketStatus":"Market Closed","change":-1.43,"latestTime":"04-04 16:00:00 EDT","open":16.48,"high":16.59,"low":15.365,"amount":39526377.639837,"amplitude":0.072101,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.591956,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":16.99,"preHourTrading":{"tag":"盘前","latestPrice":16.41,"preClose":16.99,"latestTime":"09:27 EDT","volume":2123,"amount":34529.660879999996,"timestamp":1743773260014},"postHourTrading":{"tag":"盘后","latestPrice":15.11,"preClose":15.56,"latestTime":"19:57 EDT","volume":6142,"amount":95208.1,"timestamp":1743811048583},"volumeRatio":2.2299237315780442,"impliedVol":0.6039,"impliedVolPercentile":0.8008},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","floatShares":81906729,"roa":"-4.03%","roe":"-26.63%","lyrEps":-0.591956,"volumeRatio":2.2299237315780442,"shares":91084454,"dividePrice":0,"high":16.59,"amplitude":0.072101,"preClose":16.99,"low":15.365,"week52Low":15.365,"pbRate":"10.92","psRate":"3.03","week52High":23.4,"institutionHeld":0,"latestPrice":15.56,"eps":-0.591956,"divideRate":0,"volume":2508253,"delay":0,"ttmEps":-0.591956,"open":16.48,"prevYearClose":18.26,"prevWeekClose":18.77,"prevMonthClose":18.27,"prevQuarterClose":18.27,"fiveDayClose":18.77,"twentyDayClose":17.5,"sixtyDayClose":17.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PD\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2505728270","title":"PagerDuty Report Finds A Majority of CIOs and CTOs View Agentic AI as Core to Future IT Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2505728270","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505728270?lang=en_us&edition=fundamental","pubTime":"2025-01-22 22:00","pubTimestamp":1737554400,"startTime":"0","endTime":"0","summary":"The 2025 PagerDuty State of Digital Operations Report . Data reveals a more pragmatic approach to AI adoption, prioritizing ROI on investments. SAN FRANCISCO, January 22, 2025----PagerDuty, Inc. , a global leader in digital operations management, today published the 2025 State of Digital Operations Report, which demonstrates the excitement for the business impact that AI and automation have delivered. Based on survey responses from more than 1,100 operations leaders across the North American, European, Middle Eastern, and African  and Asia-Pacific and Japan  regions, the data highlights how efficiency, security and innovation are among the top priorities shaping IT operations in 2025.The fourth edition of the State of Digital Operations Report showcases the continued maturation of digital operations over the past year, with respondents citing significant improvements in operational resilience, more effective use of automation and faster time to market. The improvements respondents repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pagerduty-report-finds-majority-cios-140000335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169589451.USD","LU1169590202.USD","PD","BK4023"],"gpt_icon":0},{"id":"2505275449","title":"Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2505275449","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505275449?lang=en_us&edition=fundamental","pubTime":"2025-01-21 22:05","pubTimestamp":1737468300,"startTime":"0","endTime":"0","summary":"SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin  with the potential to improve trabectedin’s therapeutic window in soft-tissue sarcoma patients. Combined mechanisms have the potential to enhance progression-free survival  in some of the largest cohorts of patients with soft-tissue sarcoma. Topline safety data of the combination of SON-1010 with trabectedin is expected in H2 calendar year 2025. Sonnet management discusses what this expansion means in a Virtual Investor “What This Means” segment; Access here. The Company expects to enroll up to 18 patients with unresectable, metastatic liposarcoma or leiomyosarcoma in this open-label, single-arm expansion cohort. The patients will be treated with SON-1010 in combination with the standard 21-day tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sonnet-biotherapeutics-expands-phase-1-140500403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","BK4023","BK4136","01698","PROC","LU1169589451.USD","LU0347712357.USD","BK4533","PK","BK4588","BK4567","SONN","BK4563","BK4211","IE00B12V2V27.USD","BK4571","BK4585","LU0359201612.USD","LU1721428933.USD","BK4108","LU1023057109.AUD","PFS","LU2039709279.SGD","IE00BYQNZ168.SGD","SON","LU1093756168.USD","MTD","IE00BYTNYN87.SGD","LU2413666426.HKD","BK4007","LU2413666699.HKD","BK4548","BK4552","BK4509","BK4531","BK4526","BK4565","LU0359202008.SGD","BK4195","BK4218","SG9999011746.SGD","LU1093756325.SGD","BK4181","PD","BK4535","TME","BK4139","LU1169590202.USD"],"gpt_icon":0},{"id":"2504289811","title":"3 Reasons PD is Risky and 1 Stock to Buy Instead","url":"https://stock-news.laohu8.com/highlight/detail?id=2504289811","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504289811?lang=en_us&edition=fundamental","pubTime":"2025-01-20 17:05","pubTimestamp":1737363957,"startTime":"0","endTime":"0","summary":"Over the past six months, PagerDuty’s stock price fell to $18.40. Shareholders have lost 11.8% of their capital, which is disappointing considering the S&P 500 has climbed by 7.7%. This may have investors wondering how to approach the situation.Is there a buying opportunity in PagerDuty, or does it present a risk to your portfolio?Despite the more favorable entry price, we don't have much confidence in PagerDuty. Here are three reasons why there are better opportunities than PD and a stock we'd rather own.Started by three former Amazon engineers, PagerDuty  is a software-as-a-service platform that helps companies respond to IT incidents fast and make sure that any downtime is minimized.Over the next year, analysts predict PagerDuty’s cash conversion will fall. Their consensus estimates imply its free cash flow margin of 21.8% for the last 12 months will decrease to 17%.PagerDuty isn’t a terrible business, but it doesn’t pass our bar. Following the recent decline, the stock trades at 3.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-reasons-pd-risky-1-090557179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SBC","LU1169590202.USD","LU1169589451.USD","PD","BK4023","BK4196"],"gpt_icon":0},{"id":"2503520898","title":"Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2503520898","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503520898?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:02","pubTimestamp":1736859720,"startTime":"0","endTime":"0","summary":"-- Interim data fromCohort 4 expected Q1 2025 -- MIAMI, Jan.  14, 2025  (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3009284/0/en/Pasithea-Therapeutics-Announces-Opening-of-European-Clinical-Trial-Sites-and-Completes-Initial-Dosing-of-Cohort-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4218","CNS","LENZ","PK","KTTA","LU1169590202.USD","BK4135","BK4023","BK4181","LU1169589451.USD","PD"],"gpt_icon":0},{"id":"2503520866","title":"Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection","url":"https://stock-news.laohu8.com/highlight/detail?id=2503520866","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503520866?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:00","pubTimestamp":1736859600,"startTime":"0","endTime":"0","summary":"MALVERN, Pa, Jan.  14, 2025  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a late-stage clinical drug platform company pioneering transformative therapies for neurode","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3009230/0/en/Annovis-Granted-U-S-Patent-for-Treatment-and-Prevention-of-Acute-Brain-or-Nerve-Injuries-Securing-Global-Protection.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0164881194.USD","LU0828237940.HKD","BK4523","BK4139","BK4535","LU0823039010.USD","LU0066902890.USD","IE00BYTNYM70.SGD","LU1868837722.USD","LU1868838027.USD","LU1169590202.USD","BK4207","LU0261950470.USD","IBN","LU0531971678.HKD","LU0823038988.USD","BK4023","LU0264410563.USD","LU0143863198.USD","LU0181495838.USD","LU1169589451.USD","SG9999004220.SGD","LU0048575426.USD","IE00B0JY6M65.USD","LU1481012133.USD","IE00B7N09G41.SGD","BK4585","LU0251143458.SGD","LU1102505929.USD","BK4548","PD","LU0143863784.USD","LU1868837565.USD","LU1102505762.USD","ANVS","BK4588"],"gpt_icon":0},{"id":"2503520577","title":"TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503520577","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503520577?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:00","pubTimestamp":1736859600,"startTime":"0","endTime":"0","summary":"Follows Safety Review Committee  approval based on safety data from patients in Cohorts 1 and 2. No significant safety or dose limitingtoxicities reported in Cohorts 1 and 2. BOSTON, Jan. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with TTX-MC138, its lead candidate. The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its favorable review of Cohort 1 and 2 safety and pharmacokinetic  data.Additional Cohort 3 patients have been scheduled. The dose administered to patients in the third cohort is approximately double the dose administered to those in the second cohort.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-first-patient-130000158.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-first-patient-130000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4181","BK4139","RNAZ","SRC","PD","LENZ","BK4218","LU1169590202.USD","PK","BK4080","BK4023","LU1169589451.USD","BK4231"],"gpt_icon":0},{"id":"2503573521","title":"Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2503573521","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503573521?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:00","pubTimestamp":1736856000,"startTime":"0","endTime":"0","summary":"ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3009179/0/en/Instil-Bio-Announces-Clinical-Progress-in-China-for-IMM2510-SYN-2510-a-Clinical-Stage-PD-L1xVEGF-Bispecific-Antibody.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU2039709279.SGD","IE00BYTNYN87.SGD","TIL","BK4107","BK4552","BK4548","BK4588","IE00BYQNZ168.SGD","BK4509","BK4023","BK4535","BK4531","LU1023057109.AUD","SSI","PRGS","IE00B12V2V27.USD","SG9999011746.SGD","BK4526","LU0359202008.SGD","BK4585","TME","LU1169590202.USD","BK4565","LU0053666078.USD","PD","BK4571","BK4108","LU1169589451.USD","LU2065732104.USD","BK4563","LU0359201612.USD","L","01698"],"gpt_icon":0},{"id":"2503981523","title":"Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2503981523","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503981523?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:00","pubTimestamp":1736852400,"startTime":"0","endTime":"0","summary":"‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease  years before symptoms appear, leading to new diagnostic tools and disease-modifying therapies. Part of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areas. Cutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company’s ongoing commitment to bold scientific innovation to benefit patients. The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the use of AI and integrative analysis of multiomics and real-world data in diagnostic an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grifols-pioneers-high-tech-analysis-110000974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","LU1169590202.USD","LU1169589451.USD","PD","GRFS","BK4139"],"gpt_icon":0},{"id":"2503537615","title":"PagerDuty (PD) Upgraded to Strong Buy: What Does It Mean for the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503537615","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503537615?lang=en_us&edition=fundamental","pubTime":"2025-01-14 01:00","pubTimestamp":1736787613,"startTime":"0","endTime":"0","summary":"Investors might want to bet on PagerDuty , as it has been recently upgraded to a Zacks Rank #1 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for PagerDuty basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pagerduty-pd-upgraded-strong-buy-170013856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD"],"gpt_icon":0},{"id":"2503309774","title":"Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309774","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309774?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025Preparing for commercial launch of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008476/0/en/Denali-Therapeutics-Announces-Key-Anticipated-2025-Milestones-and-Priorities-to-Further-Advance-Its-Therapeutics-Portfolio-for-Neurodegeneration-and-Lysosomal-Storage-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4548","GRN","ETV","BK4535","BK4100","BK4139","ATV","TV","LU1169590202.USD","PD","LU1169589451.USD","LENZ","DNLI"],"gpt_icon":0},{"id":"2503309098","title":"Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309098","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309098?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company’s commitment to developing genetically-validated th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008414/0/en/Alector-Reports-on-Recent-Progress-and-Outlines-Strategic-Priorities-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","PRGS","ARIA","BK4097","PD","LU1169590202.USD","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2503306807","title":"Arbutus Provides 2025 Corporate and Financial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2503306807","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503306807?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:30","pubTimestamp":1736771400,"startTime":"0","endTime":"0","summary":"Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan.  13, 2025  (GLOB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008371/14025/en/Arbutus-Provides-2025-Corporate-and-Financial-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","LU0170899867.USD","LU0321505868.SGD","BK4581","IFN","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0225284248.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU1894683348.USD","BK4007","IE0002270589.USD","LU0058720904.USD","SG9999013999.USD","NA","LU0122379950.USD","LU0321505439.SGD","LU1057294990.SGD","LU1169590202.USD","LU0985481810.HKD","SG9999002232.USD","SGXZ57979304.SGD","LU1066053197.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","LU1169589451.USD","LU1883839398.USD","BK4523","SG9999001176.SGD","BK4568","BK4592","BK4534","LU0306806265.USD","LU0289739699.SGD","LU1894683264.USD","LU0234572021.USD","LU1023059063.AUD","BK4533","PFE","BK4588","SG9999003800.SGD","BK4141","IE000M9KFDE8.USD","BK4599","PK","LU0868494617.USD","BK4023","LU0225771236.USD","PD"],"gpt_icon":1},{"id":"2502865616","title":"LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2502865616","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502865616?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:23","pubTimestamp":1736515380,"startTime":"0","endTime":"0","summary":"LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody. First-in-human study enrolling adult patients with CD123-expressing AML or MDS. “We are pleased to announce the dosing of the first patient with LAVA-1266, a potent and selective CD123-targeted Gammabody. Based on the positive results of preclinical models showing tumor cell lysis with limited off-target effects, we believe that LAVA-1266’s preclinical safety and efficacy profile supports its potential as a treatment for AML and MDS,” said Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics. “We are eager to evaluate the safety, pharmacokinetics and pharmacodynamic properties and potential activity of LAVA-1266 and provide initial results from the dose escalation study by the end of the year.”LAVA-1266 is a potent bi-specific, T cell engager  that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody platform. The bsTCE was designed to lyse CD123+ tumor cells with high potency and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lava-doses-first-patient-phase-132300036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4181","BK4218","BK4139","LU1169589451.USD","PK","PD","BK4023","LVTX","LU1169590202.USD"],"gpt_icon":0},{"id":"2502107889","title":"PagerDuty to Present at the 27th Annual Needham Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2502107889","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502107889?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:05","pubTimestamp":1736456700,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, January 09, 2025----PagerDuty, Inc. , a global leader in digital operations management, today announced that members of its management team will present at the 27th Annual Needham Growth Conference on Wednesday, January 15th, at 8am ET.PagerDuty, Inc.  is a global leader in digital operations management, enabling customers to achieve operational efficiency at scale with the PagerDuty Operations Cloud. The PagerDuty Operations Cloud combines AIOps, Automation, Customer Service Operations and Incident Management with a powerful generative AI assistant to create a flexible, resilient and scalable platform to increase innovation velocity, grow revenue, reduce cost, and mitigate the risk of operational failure. Half of the Fortune 500 and nearly 70% of the Fortune 100 rely on PagerDuty as essential infrastructure for the modern enterprise. To learn more and try PagerDuty for free, visit www.pagerduty.com.The PagerDuty Operations Cloud is the platform for mission-critical, tim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pagerduty-present-27th-annual-needham-210500482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169590202.USD","LU1169589451.USD","PD","BK4023"],"gpt_icon":0},{"id":"2501272170","title":"Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287","url":"https://stock-news.laohu8.com/highlight/detail?id=2501272170","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501272170?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., Jan. 08, 2025  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the formation of its Clinical Advisory Board  to support the continued development of the Company’s lead drug candidate, GT-02287, in Parkinson’s disease. The CAB is composed of leading experts in Parkinson’s disease trial design, genetics, and biomarkers and will work closely with Gain leadership to progress GT-02287 through potential Phase 2 and Phase 3 clinical development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gain-therapeutics-announces-formation-clinical-130000745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GT","BK4585","BK4588","LU1169589451.USD","GANX","BK4119","PD","LU1169590202.USD","BK4202","BK4139","BK4023","NCI","LENZ","CAB"],"gpt_icon":0},{"id":"2501725139","title":"Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2501725139","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501725139?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:00","pubTimestamp":1736337600,"startTime":"0","endTime":"0","summary":"- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease , has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with less drug and fewer infusions; Biologics License Application  submission on track for second half of 2025 -. - REVEAL-1 and REVEAL-2, phase 3 clinical trials for subcutaneous  VRDN-003 in active and chronic TED respectively, are currently dosing patients; topline data for both trials, which are evaluating VRDN-003 dosed Q4W or Q8W, is on track for the first half of 2026 -. \"In addition to TED, we are equally excited by the potential of our FcRn inhibitor portfolio. In Q3 of this year, we anticipate showing proof-of-concept data, including IgG reduction, from our planned VRDN-006 phase 1 clinical trial in healthy volunteers. We also continue to advance our bispecific, half-life extended, potential best-in-class VRDN-008 program. We previously showed that, in non-human prima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viridian-therapeutics-highlights-2025-corporate-120000824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAS","LU1169590202.USD","THAC","LU1169589451.USD","LDL","LENZ","BK4023","VRDN","PD","BK4139"],"gpt_icon":0},{"id":"2501302557","title":"CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2501302557","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501302557?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:05","pubTimestamp":1736283900,"startTime":"0","endTime":"0","summary":"Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two Mu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005832/0/en/CAMP4-Provides-Corporate-Updates-and-Highlights-Key-Upcoming-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4231","LU1169589451.USD","BK4200","LU1169590202.USD","ASO","BK4561","PD","BK4080","SRC"],"gpt_icon":0},{"id":"2501478730","title":"MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2501478730","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501478730?lang=en_us&edition=fundamental","pubTime":"2025-01-08 00:47","pubTimestamp":1736268424,"startTime":"0","endTime":"0","summary":"On Tuesday, MBX Biosciences Inc. revealed results from its Phase 1 single ascending dose and multiple ascending dose trial of MBX 1416 in healthy adult volunteers.MBX 1416 is the company’s investigational long-acting glucagon-like peptide 1  receptor antagonist, being developed for Post-Bariatric Hypoglycemia .PBH is a common and potentially serious complication that can occur after certain types of weight loss surgery.In the multiple ascending dose cohort, MBX 1416 median half-life was approximately 90 hours, supporting once-weekly administration, and at steady state the median Tmaxwas between 36 and 48 hours.In the multiple ascending dose cohort, MBX 1416 increased GLP-1 within 60 minutes of a mixed meal tolerance test, suggesting a pharmacodynamic  effect in healthy volunteers that may translate into a therapeutic benefit in PBH patients.Consistent with the known GLP-1 antagonism effect on gastric motility, a slight acceleration of gastric emptying was observed with MBX 1416 based o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mbx-biosciences-investigational-drug-weight-164704610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","LU1169589451.USD","LU1169590202.USD","MBX","BK4007","PBH","BK4023"],"gpt_icon":0},{"id":"2501069602","title":"FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2501069602","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501069602?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Jan.  07, 2025  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a late-stage clinical drug platform company pioneering transformative therapies ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005357/0/en/FDA-Accepts-Final-Protocol-for-Pivotal-Phase-3-Alzheimer-s-Disease-Study-Streamlining-Development-Pathway.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","LU1102505929.USD","LU0164881194.USD","LU1868838027.USD","BK4023","LU0066902890.USD","BK4588","LU0181495838.USD","BK4548","BK4523","LU1868837722.USD","LU0251143458.SGD","LU0264410563.USD","PD","LU0823038988.USD","LU1169589451.USD","IE00B0JY6M65.USD","LU0048575426.USD","LU1102505762.USD","BK4139","LU1868837565.USD","LU1481012133.USD","ANVS","IE00B7N09G41.SGD","LU1169590202.USD","IE00BYTNYM70.SGD","LU0143863784.USD","LU0531971678.HKD","LU0823039010.USD","BK4207","LU0261950470.USD","IBN","LU0143863198.USD","LU0828237940.HKD","BK4585","BK4535"],"gpt_icon":0},{"id":"2501827032","title":"Press Release: Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2501827032","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501827032?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:00","pubTimestamp":1736251200,"startTime":"0","endTime":"0","summary":"Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024. Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance. Gene Mack, newly appointed CEO of Gain, added, \"I am honored by the opportunity to lead the passionate team we have here at Gain -- a team that I have grown very fond of after experiencing firsthand during 2024 how uniformly committed everyone is to our mission of developing truly disease-altering treatments that go beyond temporary symptom relief. I look forward to providing continuing support and contributing to the impressive work being done by my colleagues at Gain as we guide our lead candidate, GT-02287, through the currently ongoing Phase 1b trial in people with Parkinson's Disease during the first half of 2025, while also preparing for potential Phase 2 activities during the second half of 2025.\". Gene has over 25 years of experience in the life sciences sector spanning clinical research, financing and capital markets, investing","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4119","BK4023","BK4555","BK4585","BK4588","03160","LU1169589451.USD","LU1169590202.USD","PD","BK4139","GT","LENZ","GANX","MSD","TM","BK4099"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"PD","fiscalQuarterEnding":"2025/01","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-11-26","symbol":"PD","fiscalQuarterEnding":"2024/10","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2024-09-03","symbol":"PD","fiscalQuarterEnding":"2024/07","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-05-30","symbol":"PD","fiscalQuarterEnding":"2024/04","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1717041600000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2024-03-14","symbol":"PD","fiscalQuarterEnding":"2024/01","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710388800000,"reportTimeType":"post","actualEps":-0.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0769,"buy":0.3077,"hold":0.4615,"sell":0.1538,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.4615,"analysts":13,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PD","date":"2025-04-04","current":-28.415807,"percent":0.417219,"low":-81.051795,"twenty":-43.157994,"median":-25.140052,"eighty":-20.118618,"high":-13.794086,"avg":-30.698022,"sd":13.437856,"marketCap":1547524873},"quantilePoints":[{"date":"2020-04-09","current":-28.429956,"twenty":-77.931632,"median":-44.243832,"eighty":-37.508627,"marketCap":1431135564},{"date":"2020-04-17","current":-32.325741,"twenty":-77.435709,"median":-43.781756,"eighty":-36.980797,"marketCap":1627245494},{"date":"2020-04-24","current":-33.176012,"twenty":-77.284281,"median":-43.600226,"eighty":-36.837683,"marketCap":1670047265},{"date":"2020-05-01","current":-32.047471,"twenty":-76.727947,"median":-43.369188,"eighty":-36.303053,"marketCap":1613237642},{"date":"2020-05-08","current":-38.278643,"twenty":-76.441551,"median":-43.006127,"eighty":-35.678665,"marketCap":1926908589},{"date":"2020-05-15","current":-40.070276,"twenty":-76.181489,"median":-42.907111,"eighty":-35.799269,"marketCap":2017097635},{"date":"2020-05-22","current":-43.435432,"twenty":-76.082732,"median":-42.504512,"eighty":-36.303053,"marketCap":2186496193},{"date":"2020-05-29","current":-41.363368,"twenty":-75.845714,"median":-42.329073,"eighty":-36.388531,"marketCap":2082190599},{"date":"2020-06-05","current":-41.572682,"twenty":-75.735317,"median":-42.449993,"eighty":-36.532943,"marketCap":2067575752},{"date":"2020-06-12","current":-39.198908,"twenty":-75.187331,"median":-42.329073,"eighty":-36.817602,"marketCap":1949518515},{"date":"2020-06-19","current":-48.393323,"twenty":-74.002242,"median":-42.496137,"eighty":-36.834452,"marketCap":2406793548},{"date":"2020-06-26","current":-46.067026,"twenty":-73.969323,"median":-42.888728,"eighty":-36.850607,"marketCap":2291097455},{"date":"2020-07-02","current":-47.49129,"twenty":-73.92982,"median":-42.964871,"eighty":-36.863809,"marketCap":2361931798},{"date":"2020-07-10","current":-44.658587,"twenty":-72.98504,"median":-43.055636,"eighty":-36.906716,"marketCap":2221050161},{"date":"2020-07-17","current":-40.765599,"twenty":-72.685476,"median":-42.964871,"eighty":-36.931288,"marketCap":2027436292},{"date":"2020-07-24","current":-42.807044,"twenty":-72.640646,"median":-42.989625,"eighty":-37.118318,"marketCap":2128965516},{"date":"2020-07-31","current":-48.235072,"twenty":-72.530247,"median":-43.175427,"eighty":-37.208604,"marketCap":2398923066},{"date":"2020-08-07","current":-47.238087,"twenty":-72.318638,"median":-43.360924,"eighty":-37.407321,"marketCap":2349339026},{"date":"2020-08-14","current":-46.177802,"twenty":-72.098738,"median":-43.468321,"eighty":-37.467623,"marketCap":2296606793},{"date":"2020-08-21","current":-45.95625,"twenty":-71.69039,"median":-43.550826,"eighty":-37.518859,"marketCap":2285588118},{"date":"2020-08-28","current":-48.583225,"twenty":-71.41486,"median":-43.699242,"eighty":-37.630539,"marketCap":2416238127},{"date":"2020-09-04","current":-38.528058,"twenty":-71.368789,"median":-43.748751,"eighty":-37.658486,"marketCap":1997756875},{"date":"2020-09-11","current":-36.766338,"twenty":-71.24954,"median":-43.637964,"eighty":-37.464273,"marketCap":1906408152},{"date":"2020-09-18","current":-38.03784,"twenty":-70.931543,"median":-43.525964,"eighty":-37.424178,"marketCap":1972338100},{"date":"2020-09-25","current":-40.596165,"twenty":-70.750862,"median":-43.369188,"eighty":-37.464273,"marketCap":2104992334},{"date":"2020-10-02","current":-42.378825,"twenty":-69.760733,"median":-43.304333,"eighty":-37.506887,"marketCap":2197426830},{"date":"2020-10-09","current":-45.308378,"twenty":-68.893466,"median":-43.360924,"eighty":-37.540906,"marketCap":2349330024},{"date":"2020-10-16","current":-46.719472,"twenty":-68.681421,"median":-43.459295,"eighty":-37.566006,"marketCap":2422498055},{"date":"2020-10-23","current":-44.664183,"twenty":-67.026675,"median":-43.550718,"eighty":-37.624584,"marketCap":2315927228},{"date":"2020-10-30","current":-41.565912,"twenty":-65.321463,"median":-43.550772,"eighty":-37.657731,"marketCap":2155275682},{"date":"2020-11-06","current":-46.121291,"twenty":-64.742086,"median":-43.550826,"eighty":-37.676934,"marketCap":2391481172},{"date":"2020-11-13","current":-46.35136,"twenty":-63.787431,"median":-43.643849,"eighty":-37.728931,"marketCap":2403410742},{"date":"2020-11-20","current":-47.79313,"twenty":-62.855819,"median":-43.781756,"eighty":-37.757248,"marketCap":2478169382},{"date":"2020-11-27","current":-52.440537,"twenty":-62.329113,"median":-43.973974,"eighty":-37.811067,"marketCap":2719146700},{"date":"2020-12-04","current":-58.503982,"twenty":-61.897872,"median":-44.116471,"eighty":-37.910083,"marketCap":3346135266},{"date":"2020-12-11","current":-61.956348,"twenty":-61.897872,"median":-44.23472,"eighty":-37.979009,"marketCap":3543593297},{"date":"2020-12-18","current":-64.76408,"twenty":-63.261641,"median":-44.342085,"eighty":-38.134161,"marketCap":3704181571},{"date":"2020-12-24","current":-65.981719,"twenty":-64.468982,"median":-44.366057,"eighty":-38.286785,"marketCap":3773824445},{"date":"2020-12-31","current":-59.735947,"twenty":-64.377301,"median":-44.622066,"eighty":-38.319351,"marketCap":3416597468},{"date":"2021-01-08","current":-63.775644,"twenty":-64.248374,"median":-44.664183,"eighty":-38.342002,"marketCap":3647647944},{"date":"2021-01-15","current":-65.265461,"twenty":-64.491902,"median":-44.85652,"eighty":-38.342002,"marketCap":3732858049},{"date":"2021-01-22","current":-70.007091,"twenty":-64.924465,"median":-44.940871,"eighty":-38.368803,"marketCap":4004055593},{"date":"2021-01-29","current":-69.806539,"twenty":-66.010369,"median":-45.124322,"eighty":-38.447577,"marketCap":3992585002},{"date":"2021-02-05","current":-78.774094,"twenty":-67.606194,"median":-45.279297,"eighty":-38.515566,"marketCap":4505484287},{"date":"2021-02-12","current":-81.051795,"twenty":-68.875403,"median":-45.308378,"eighty":-38.533013,"marketCap":4635757427},{"date":"2021-02-19","current":-74.533844,"twenty":-69.256452,"median":-45.492434,"eighty":-38.599807,"marketCap":4262963219},{"date":"2021-02-26","current":-64.090797,"twenty":-69.256452,"median":-45.616009,"eighty":-38.656949,"marketCap":3665673158},{"date":"2021-03-05","current":-53.862628,"twenty":-69.159583,"median":-45.671397,"eighty":-38.66724,"marketCap":3080673016},{"date":"2021-03-12","current":-60.509506,"twenty":-69.072496,"median":-45.726784,"eighty":-38.673459,"marketCap":3460841176},{"date":"2021-03-19","current":-49.639711,"twenty":-68.918379,"median":-45.797998,"eighty":-38.687063,"marketCap":3420324980},{"date":"2021-03-26","current":-46.372989,"twenty":-68.782324,"median":-45.852876,"eighty":-38.706425,"marketCap":3195238028},{"date":"2021-04-01","current":-49.627656,"twenty":-68.703922,"median":-45.852876,"eighty":-38.74149,"marketCap":3419494401},{"date":"2021-04-09","current":-50.688437,"twenty":-68.634603,"median":-45.95625,"eighty":-38.792193,"marketCap":3492585367},{"date":"2021-04-16","current":-50.965686,"twenty":-68.620415,"median":-46.098464,"eighty":-38.810779,"marketCap":3511688688},{"date":"2021-04-23","current":-50.965686,"twenty":-68.551655,"median":-46.177802,"eighty":-38.849388,"marketCap":3511688688},{"date":"2021-04-30","current":-51.182664,"twenty":-68.073194,"median":-46.296231,"eighty":-38.932876,"marketCap":3526639113},{"date":"2021-05-07","current":-45.52431,"twenty":-67.425697,"median":-46.35136,"eighty":-39.005886,"marketCap":3136761501},{"date":"2021-05-14","current":-42.286432,"twenty":-67.150653,"median":-46.187891,"eighty":-39.046881,"marketCap":2913662055},{"date":"2021-05-21","current":-44.081211,"twenty":-66.824039,"median":-46.121291,"eighty":-39.054259,"marketCap":3037327665},{"date":"2021-05-28","current":-49.295769,"twenty":-66.574781,"median":-46.172553,"eighty":-39.081958,"marketCap":3396626399},{"date":"2021-06-04","current":-36.968776,"twenty":-66.216652,"median":-46.172553,"eighty":-39.072116,"marketCap":2957576028},{"date":"2021-06-11","current":-42.279901,"twenty":-66.096321,"median":-46.075636,"eighty":-39.072116,"marketCap":3382476656},{"date":"2021-06-18","current":-45.709132,"twenty":-65.976077,"median":-45.923735,"eighty":-39.125091,"marketCap":3656821944},{"date":"2021-06-25","current":-47.162372,"twenty":-65.815901,"median":-46.067026,"eighty":-39.183405,"marketCap":3773084124},{"date":"2021-07-02","current":-44.130431,"twenty":-65.216755,"median":-46.011638,"eighty":-39.205083,"marketCap":3530522741},{"date":"2021-07-09","current":-45.834591,"twenty":-65.021933,"median":-45.883552,"eighty":-39.229781,"marketCap":3666858967},{"date":"2021-07-16","current":-40.199362,"twenty":-64.900098,"median":-45.829869,"eighty":-39.313533,"marketCap":3216029363},{"date":"2021-07-23","current":-43.325398,"twenty":-64.76408,"median":-45.766347,"eighty":-39.330284,"marketCap":3466118512},{"date":"2021-07-30","current":-42.436726,"twenty":-64.636745,"median":-45.712576,"eighty":-39.369202,"marketCap":3395022935},{"date":"2021-08-06","current":-44.33953,"twenty":-64.491902,"median":-45.685037,"eighty":-39.631794,"marketCap":3547251112},{"date":"2021-08-13","current":-42.269446,"twenty":-64.377301,"median":-45.655572,"eighty":-39.648544,"marketCap":3381640238},{"date":"2021-08-20","current":-40.387552,"twenty":-64.32,"median":-45.516041,"eighty":-39.732297,"marketCap":3231084897},{"date":"2021-08-27","current":-43.743597,"twenty":-64.248374,"median":-45.492434,"eighty":-39.784241,"marketCap":3499575255},{"date":"2021-09-03","current":-42.390054,"twenty":-64.090797,"median":-45.440934,"eighty":-39.784241,"marketCap":4025995391},{"date":"2021-09-10","current":-39.410762,"twenty":-63.838675,"median":-45.357157,"eighty":-39.773852,"marketCap":3743037083},{"date":"2021-09-17","current":-42.488469,"twenty":-63.43184,"median":-45.291593,"eighty":-39.773852,"marketCap":4035342362},{"date":"2021-09-24","current":-41.531159,"twenty":-63.322968,"median":-45.131991,"eighty":-39.806871,"marketCap":3944421825},{"date":"2021-10-01","current":-37.845067,"twenty":-63.294318,"median":-44.969953,"eighty":-39.673042,"marketCap":3594335269},{"date":"2021-10-08","current":-35.304169,"twenty":-63.234694,"median":-44.895964,"eighty":-39.361418,"marketCap":3353013468},{"date":"2021-10-15","current":-36.968279,"twenty":-62.977151,"median":-44.757709,"eighty":-39.195032,"marketCap":3511062253},{"date":"2021-10-22","current":-37.567716,"twenty":-62.673,"median":-44.689179,"eighty":-39.048237,"marketCap":3567993805},{"date":"2021-10-29","current":-37.352992,"twenty":-62.144822,"median":-44.662724,"eighty":-38.884343,"marketCap":3547600413},{"date":"2021-11-05","current":-38.927633,"twenty":-61.970673,"median":-44.622066,"eighty":-38.780249,"marketCap":3697151952},{"date":"2021-11-12","current":-37.684024,"twenty":-61.914834,"median":-44.517265,"eighty":-38.690435,"marketCap":3579040225},{"date":"2021-11-19","current":-34.892615,"twenty":-61.891288,"median":-44.350719,"eighty":-38.663132,"marketCap":3313926135},{"date":"2021-11-26","current":-33.094304,"twenty":-61.87812,"median":-44.340807,"eighty":-38.647574,"marketCap":3143131480},{"date":"2021-12-03","current":-27.717262,"twenty":-61.851785,"median":-44.310434,"eighty":-38.490518,"marketCap":2632446965},{"date":"2021-12-10","current":-29.437491,"twenty":-61.634212,"median":-44.193031,"eighty":-38.342002,"marketCap":2964590848},{"date":"2021-12-17","current":-29.446029,"twenty":-61.446371,"median":-44.130431,"eighty":-38.122419,"marketCap":2965450648},{"date":"2021-12-23","current":-30.863263,"twenty":-61.141525,"median":-44.120926,"eighty":-37.910083,"marketCap":3108177469},{"date":"2021-12-31","current":-29.668005,"twenty":-60.679678,"median":-44.096614,"eighty":-37.767931,"marketCap":2987805451},{"date":"2022-01-07","current":-27.243339,"twenty":-60.561077,"median":-44.020576,"eighty":-37.685906,"marketCap":2743622214},{"date":"2022-01-14","current":-26.466422,"twenty":-60.402519,"median":-43.931787,"eighty":-37.609143,"marketCap":2665380403},{"date":"2022-01-21","current":-25.715117,"twenty":-60.229637,"median":-43.82863,"eighty":-37.535067,"marketCap":2589717991},{"date":"2022-01-28","current":-27.448241,"twenty":-60.179262,"median":-43.748751,"eighty":-37.457573,"marketCap":2764257417},{"date":"2022-02-04","current":-27.106738,"twenty":-60.125395,"median":-43.643849,"eighty":-37.310047,"marketCap":2729865412},{"date":"2022-02-11","current":-28.728874,"twenty":-59.884929,"median":-43.550718,"eighty":-37.143446,"marketCap":2893227437},{"date":"2022-02-18","current":-27.106738,"twenty":-59.724487,"median":-43.492185,"eighty":-36.968378,"marketCap":2729865412},{"date":"2022-02-25","current":-28.071482,"twenty":-59.678646,"median":-43.437917,"eighty":-36.905651,"marketCap":2827022827},{"date":"2022-03-04","current":-25.322389,"twenty":-59.583656,"median":-43.360924,"eighty":-36.834452,"marketCap":2550167185},{"date":"2022-03-11","current":-22.70136,"twenty":-59.306192,"median":-43.319423,"eighty":-36.766338,"marketCap":2286208545},{"date":"2022-03-18","current":-28.291592,"twenty":-59.172166,"median":-43.295217,"eighty":-36.444632,"marketCap":3040073042},{"date":"2022-03-25","current":-28.785804,"twenty":-59.048339,"median":-43.241759,"eighty":-36.064649,"marketCap":3093178556},{"date":"2022-04-01","current":-27.724464,"twenty":-59.048339,"median":-43.1764,"eighty":-35.678665,"marketCap":2979132288},{"date":"2022-04-08","current":-25.415442,"twenty":-58.958192,"median":-43.086807,"eighty":-35.293402,"marketCap":2731016361},{"date":"2022-04-14","current":-26.428171,"twenty":-58.866018,"median":-43.039133,"eighty":-34.945236,"marketCap":2839839136},{"date":"2022-04-22","current":-23.843687,"twenty":-58.778063,"median":-42.940117,"eighty":-34.48789,"marketCap":2562123414},{"date":"2022-04-29","current":-23.14693,"twenty":-58.704534,"median":-42.888728,"eighty":-33.407653,"marketCap":2487253345},{"date":"2022-05-06","current":-21.039181,"twenty":-58.614907,"median":-42.82356,"eighty":-33.196501,"marketCap":2260765197},{"date":"2022-05-13","current":-21.537198,"twenty":-58.533862,"median":-42.744231,"eighty":-33.138326,"marketCap":2314279623},{"date":"2022-05-20","current":-19.528801,"twenty":-58.506847,"median":-42.67719,"eighty":-32.784627,"marketCap":2098467346},{"date":"2022-05-27","current":-21.055509,"twenty":-58.47232,"median":-42.506172,"eighty":-32.56425,"marketCap":2262519768},{"date":"2022-06-03","current":-19.41561,"twenty":-58.365647,"median":-42.492303,"eighty":-32.253988,"marketCap":2285547362},{"date":"2022-06-10","current":-18.661968,"twenty":-58.119439,"median":-42.449993,"eighty":-31.627913,"marketCap":2196830881},{"date":"2022-06-17","current":-17.871017,"twenty":-57.794408,"median":-42.412967,"eighty":-30.853018,"marketCap":2103722495},{"date":"2022-06-24","current":-21.251213,"twenty":-57.545961,"median":-42.37641,"eighty":-30.527663,"marketCap":2501629088},{"date":"2022-07-01","current":-18.975364,"twenty":-57.27835,"median":-42.328632,"eighty":-30.205871,"marketCap":2233722883},{"date":"2022-07-08","current":-20.758734,"twenty":-57.119373,"median":-42.300639,"eighty":-29.937792,"marketCap":2443655942},{"date":"2022-07-15","current":-19.512613,"twenty":-57.022546,"median":-42.274674,"eighty":-29.686169,"marketCap":2296966315},{"date":"2022-07-22","current":-19.751391,"twenty":-56.538634,"median":-42.258991,"eighty":-29.576542,"marketCap":2325074507},{"date":"2022-07-29","current":-19.348454,"twenty":-55.37095,"median":-42.1379,"eighty":-29.489533,"marketCap":2277641933},{"date":"2022-08-05","current":-21.340755,"twenty":-54.581356,"median":-41.999461,"eighty":-29.249821,"marketCap":2512169660},{"date":"2022-08-12","current":-21.370602,"twenty":-54.282209,"median":-41.907002,"eighty":-28.899625,"marketCap":2515683184},{"date":"2022-08-19","current":-19.214141,"twenty":-54.164004,"median":-41.742363,"eighty":-28.761236,"marketCap":2261831075},{"date":"2022-08-26","current":-19.318607,"twenty":-54.013801,"median":-41.687142,"eighty":-28.490216,"marketCap":2274128409},{"date":"2022-09-02","current":-16.562766,"twenty":-53.825684,"median":-41.612639,"eighty":-28.401837,"marketCap":2096100841},{"date":"2022-09-09","current":-17.753369,"twenty":-53.67791,"median":-41.5952,"eighty":-28.368118,"marketCap":2246777593},{"date":"2022-09-16","current":-16.597991,"twenty":-53.584381,"median":-41.569297,"eighty":-28.257217,"marketCap":2100558733},{"date":"2022-09-23","current":-15.858267,"twenty":-53.533149,"median":-41.530643,"eighty":-28.105632,"marketCap":2006943000},{"date":"2022-09-30","current":-16.252786,"twenty":-53.345477,"median":-41.466004,"eighty":-27.873415,"marketCap":2056871391},{"date":"2022-10-07","current":-16.182337,"twenty":-53.110426,"median":-41.390601,"eighty":-27.717262,"marketCap":2047955607},{"date":"2022-10-14","current":-14.646529,"twenty":-52.79331,"median":-41.34773,"eighty":-27.636067,"marketCap":1853591514},{"date":"2022-10-21","current":-16.485271,"twenty":-52.578578,"median":-41.307589,"eighty":-27.328715,"marketCap":2086293479},{"date":"2022-10-28","current":-17.922449,"twenty":-52.484531,"median":-41.281723,"eighty":-27.012825,"marketCap":2268175475},{"date":"2022-11-04","current":-14.604259,"twenty":-52.445692,"median":-41.223096,"eighty":-26.683037,"marketCap":1848242043},{"date":"2022-11-11","current":-17.35885,"twenty":-52.440537,"median":-41.165581,"eighty":-26.46868,"marketCap":2196849202},{"date":"2022-11-18","current":-15.442613,"twenty":-51.97825,"median":-41.046215,"eighty":-26.415612,"marketCap":1954339874},{"date":"2022-11-25","current":-15.379208,"twenty":-51.971496,"median":-40.952393,"eighty":-26.24103,"marketCap":1946315669},{"date":"2022-12-02","current":-16.042428,"twenty":-51.941247,"median":-40.886211,"eighty":-26.002015,"marketCap":2129728606},{"date":"2022-12-09","current":-16.110204,"twenty":-51.872986,"median":-40.837833,"eighty":-25.713912,"marketCap":2138726192},{"date":"2022-12-16","current":-18.028246,"twenty":-51.7604,"median":-40.772608,"eighty":-25.598799,"marketCap":2393357876},{"date":"2022-12-23","current":-17.994359,"twenty":-51.70784,"median":-40.745253,"eighty":-25.338499,"marketCap":2388859083},{"date":"2022-12-30","current":-18.001136,"twenty":-51.570726,"median":-40.701201,"eighty":-25.184081,"marketCap":2389758841},{"date":"2023-01-06","current":-16.049206,"twenty":-51.363479,"median":-40.623172,"eighty":-24.85486,"marketCap":2130628364},{"date":"2023-01-13","current":-18.78733,"twenty":-51.102161,"median":-40.574619,"eighty":-24.231092,"marketCap":2494130839},{"date":"2023-01-20","current":-18.882216,"twenty":-50.978262,"median":-40.523325,"eighty":-23.99114,"marketCap":2506727459},{"date":"2023-01-27","current":-19.925957,"twenty":-50.965686,"median":-40.469321,"eighty":-23.312385,"marketCap":2645290284},{"date":"2023-02-03","current":-21.220466,"twenty":-50.951221,"median":-40.311267,"eighty":-22.57339,"marketCap":2817144176},{"date":"2023-02-10","current":-19.627745,"twenty":-50.890949,"median":-40.250171,"eighty":-21.596594,"marketCap":2605700905},{"date":"2023-02-17","current":-20.664708,"twenty":-50.876484,"median":-40.190227,"eighty":-21.430411,"marketCap":2743363971},{"date":"2023-02-24","current":-19.485417,"twenty":-50.857197,"median":-40.120759,"eighty":-21.251213,"marketCap":2586805975},{"date":"2023-03-03","current":-20.834146,"twenty":-50.688437,"median":-40.045986,"eighty":-21.055509,"marketCap":2765857936},{"date":"2023-03-10","current":-18.204462,"twenty":-50.646894,"median":-39.953806,"eighty":-20.967665,"marketCap":2416751599},{"date":"2023-03-17","current":-22.814647,"twenty":-50.628165,"median":-39.81605,"eighty":-20.881589,"marketCap":2929925462},{"date":"2023-03-24","current":-22.508745,"twenty":-50.547877,"median":-39.758269,"eighty":-20.937818,"marketCap":2890640524},{"date":"2023-03-31","current":-24.884826,"twenty":-50.538628,"median":-39.648544,"eighty":-20.967665,"marketCap":3195783993},{"date":"2023-04-06","current":-22.608341,"twenty":-50.398102,"median":-39.410762,"eighty":-20.985573,"marketCap":2903430969},{"date":"2023-04-14","current":-23.753697,"twenty":-50.260054,"median":-39.321908,"eighty":-21.029355,"marketCap":3050521084},{"date":"2023-04-21","current":-24.273021,"twenty":-50.211876,"median":-39.198908,"eighty":-21.041663,"marketCap":3117214118},{"date":"2023-04-28","current":-22.053448,"twenty":-50.10983,"median":-39.086878,"eighty":-21.052864,"marketCap":2832169920},{"date":"2023-05-05","current":-20.085339,"twenty":-50.030853,"median":-39.045525,"eighty":-21.029355,"marketCap":2579419472},{"date":"2023-05-12","current":-21.254175,"twenty":-50.011348,"median":-38.97946,"eighty":-20.981096,"marketCap":2729524925},{"date":"2023-05-19","current":-21.074906,"twenty":-49.936988,"median":-38.858126,"eighty":-20.935287,"marketCap":2706502616},{"date":"2023-05-26","current":-18.98821,"twenty":-49.739821,"median":-38.781427,"eighty":-20.865452,"marketCap":2438522942},{"date":"2023-06-02","current":-23.7011,"twenty":-49.634889,"median":-38.748697,"eighty":-20.83367,"marketCap":2555476271},{"date":"2023-06-09","current":-19.16437,"twenty":-49.587066,"median":-38.685442,"eighty":-20.780404,"marketCap":2066321490},{"date":"2023-06-16","current":-19.591955,"twenty":-49.518553,"median":-38.668128,"eighty":-20.758997,"marketCap":2112424156},{"date":"2023-06-23","current":-18.642716,"twenty":-49.490829,"median":-38.652026,"eighty":-20.740419,"marketCap":2010076237},{"date":"2023-06-30","current":-18.830853,"twenty":-49.425691,"median":-38.650282,"eighty":-20.728887,"marketCap":2030361410},{"date":"2023-07-07","current":-18.753888,"twenty":-49.321753,"median":-38.534252,"eighty":-20.640309,"marketCap":2022062930},{"date":"2023-07-14","current":-21.12271,"twenty":-49.135663,"median":-38.486364,"eighty":-20.586625,"marketCap":2277471700},{"date":"2023-07-21","current":-20.626711,"twenty":-49.077653,"median":-38.375503,"eighty":-20.595005,"marketCap":2223992607},{"date":"2023-07-28","current":-21.105606,"twenty":-49.061015,"median":-38.330676,"eighty":-20.595005,"marketCap":2275627593},{"date":"2023-08-04","current":-20.883262,"twenty":-49.007339,"median":-38.158206,"eighty":-20.613914,"marketCap":2251654207},{"date":"2023-08-11","current":-20.549746,"twenty":-48.954208,"median":-37.988814,"eighty":-20.586625,"marketCap":2215694127},{"date":"2023-08-18","current":-20.01954,"twenty":-48.941266,"median":-37.845067,"eighty":-20.541194,"marketCap":2158526822},{"date":"2023-08-25","current":-20.66947,"twenty":-48.894876,"median":-37.770349,"eighty":-20.506987,"marketCap":2228602874},{"date":"2023-09-01","current":-25.511357,"twenty":-48.832826,"median":-37.755599,"eighty":-20.541194,"marketCap":2375209352},{"date":"2023-09-07","current":-24.043412,"twenty":-48.807682,"median":-37.686377,"eighty":-20.560008,"marketCap":2238537799},{"date":"2023-09-14","current":-23.412009,"twenty":-48.750972,"median":-37.671633,"eighty":-20.577111,"marketCap":2179751687},{"date":"2023-09-22","current":-22.590183,"twenty":-48.595885,"median":-37.578261,"eighty":-20.58462,"marketCap":2103236431},{"date":"2023-09-28","current":-22.048981,"twenty":-48.583225,"median":-37.547623,"eighty":-20.587293,"marketCap":2052848336},{"date":"2023-10-05","current":-21.978825,"twenty":-48.576545,"median":-37.531928,"eighty":-20.595005,"marketCap":2046316545},{"date":"2023-10-11","current":-21.497757,"twenty":-48.562801,"median":-37.500901,"eighty":-20.605423,"marketCap":2001527127},{"date":"2023-10-20","current":-20.345196,"twenty":-48.534663,"median":-37.448341,"eighty":-20.589221,"marketCap":1894219146},{"date":"2023-10-27","current":-19.894194,"twenty":-48.514606,"median":-37.410785,"eighty":-20.580532,"marketCap":1852229066},{"date":"2023-11-03","current":-20.485508,"twenty":-48.433814,"median":-37.299311,"eighty":-20.506205,"marketCap":1907282726},{"date":"2023-11-10","current":-20.746087,"twenty":-48.370598,"median":-37.219715,"eighty":-20.506987,"marketCap":1931543661},{"date":"2023-11-17","current":-21.217133,"twenty":-48.32991,"median":-37.120374,"eighty":-20.524091,"marketCap":1975399966},{"date":"2023-11-24","current":-21.858558,"twenty":-48.320008,"median":-37.057747,"eighty":-20.549746,"marketCap":2035119191},{"date":"2023-11-30","current":-22.048981,"twenty":-48.252059,"median":-36.968279,"eighty":-20.57027,"marketCap":2052848336},{"date":"2023-12-07","current":-26.625426,"twenty":-48.121131,"median":-36.925787,"eighty":-20.578821,"marketCap":2015198621},{"date":"2023-12-15","current":-28.276615,"twenty":-48.00719,"median":-36.911135,"eighty":-20.582242,"marketCap":2140172179},{"date":"2024-01-05","current":-26.103359,"twenty":-47.918569,"median":-36.904212,"eighty":-20.585288,"marketCap":1975684923},{"date":"2024-01-12","current":-31.117632,"twenty":-47.865829,"median":-36.842529,"eighty":-20.591149,"marketCap":2355200212},{"date":"2024-01-19","current":-31.627558,"twenty":-47.844972,"median":-36.829603,"eighty":-20.601178,"marketCap":2393794988},{"date":"2024-01-26","current":-29.053645,"twenty":-47.78321,"median":-36.766338,"eighty":-20.619869,"marketCap":2198983265},{"date":"2024-02-02","current":-29.32075,"twenty":-47.731847,"median":-36.504107,"eighty":-20.628421,"marketCap":2219199576},{"date":"2024-02-09","current":-29.393596,"twenty":-47.672575,"median":-36.388531,"eighty":-20.635263,"marketCap":2224713115},{"date":"2024-02-16","current":-29.733547,"twenty":-47.618326,"median":-36.095963,"eighty":-20.635379,"marketCap":2250442965},{"date":"2024-02-23","current":-28.10664,"twenty":-47.602066,"median":-35.89466,"eighty":-20.635842,"marketCap":2127307254},{"date":"2024-03-01","current":-29.332891,"twenty":-47.570415,"median":-35.678665,"eighty":-20.651153,"marketCap":2220118499},{"date":"2024-03-08","current":-29.55143,"twenty":-47.518149,"median":-35.35785,"eighty":-20.660918,"marketCap":2236659117},{"date":"2024-03-15","current":-26.009561,"twenty":-47.49129,"median":-35.24315,"eighty":-20.664708,"marketCap":2126463652},{"date":"2024-03-22","current":-25.786705,"twenty":-47.380514,"median":-34.925503,"eighty":-20.66947,"marketCap":2108243640},{"date":"2024-03-28","current":-24.935846,"twenty":-47.342533,"median":-34.589879,"eighty":-20.66947,"marketCap":2038679948},{"date":"2024-04-05","current":-25.071983,"twenty":-47.312176,"median":-34.414946,"eighty":-20.689994,"marketCap":2049810139},{"date":"2024-04-12","current":-25.888808,"twenty":-47.269427,"median":-33.423363,"eighty":-20.697474,"marketCap":2116591283},{"date":"2024-04-19","current":-23.631195,"twenty":-47.158961,"median":-33.184171,"eighty":-20.697474,"marketCap":1932015619},{"date":"2024-04-26","current":-22.916473,"twenty":-46.951231,"median":-33.003753,"eighty":-20.698257,"marketCap":1873582118},{"date":"2024-05-03","current":-23.897861,"twenty":-46.656905,"median":-32.649248,"eighty":-20.698257,"marketCap":1953817432},{"date":"2024-05-10","current":-23.114516,"twenty":-46.598159,"median":-32.247909,"eighty":-20.698257,"marketCap":1889773514},{"date":"2024-05-17","current":-24.517522,"twenty":-46.43348,"median":-31.759443,"eighty":-20.698257,"marketCap":2004479038},{"date":"2024-05-24","current":-22.904066,"twenty":-46.181838,"median":-31.451512,"eighty":-20.698257,"marketCap":1872567685},{"date":"2024-05-31","current":-20.986625,"twenty":-46.068748,"median":-31.128449,"eighty":-20.698257,"marketCap":1715803469},{"date":"2024-06-07","current":-20.224161,"twenty":-45.830813,"median":-30.643949,"eighty":-20.66395,"marketCap":1892880316},{"date":"2024-06-14","current":-21.429439,"twenty":-45.725202,"median":-30.31849,"eighty":-20.645029,"marketCap":2005688335},{"date":"2024-06-21","current":-21.357939,"twenty":-45.671397,"median":-29.967092,"eighty":-20.641966,"marketCap":1998996334},{"date":"2024-06-28","current":-23.247571,"twenty":-45.51108,"median":-29.932669,"eighty":-20.635726,"marketCap":2175856364},{"date":"2024-07-05","current":-22.542789,"twenty":-45.42729,"median":-29.794252,"eighty":-20.635726,"marketCap":2109892353},{"date":"2024-07-12","current":-21.439653,"twenty":-45.27192,"median":-29.668005,"eighty":-20.635726,"marketCap":2006644335},{"date":"2024-07-15","current":-21.807365,"twenty":-45.165128,"median":-29.6527,"eighty":-20.635726,"marketCap":2041060341},{"date":"2024-08-02","current":-20.438659,"twenty":-44.67116,"median":-29.473821,"eighty":-20.619869,"marketCap":1912956320},{"date":"2024-08-09","current":-18.937169,"twenty":-44.592228,"median":-29.326821,"eighty":-20.554877,"marketCap":1772424296},{"date":"2024-08-16","current":-19.846234,"twenty":-44.342086,"median":-29.065787,"eighty":-20.488395,"marketCap":1857508310},{"date":"2024-08-23","current":-19.366166,"twenty":-44.293477,"median":-28.968658,"eighty":-20.439367,"marketCap":1812576303},{"date":"2024-08-30","current":-20.193518,"twenty":-44.126836,"median":-28.878841,"eighty":-20.396729,"marketCap":1890012316},{"date":"2024-09-06","current":-20.851386,"twenty":-44.070828,"median":-28.815003,"eighty":-20.350301,"marketCap":1731811836},{"date":"2024-09-13","current":-19.495653,"twenty":-43.902513,"median":-28.750118,"eighty":-20.261779,"marketCap":1619211496},{"date":"2024-09-20","current":-20.358392,"twenty":-43.724824,"median":-28.493474,"eighty":-20.244564,"marketCap":1690866258},{"date":"2024-09-27","current":-20.324779,"twenty":-43.52784,"median":-28.425739,"eighty":-20.226358,"marketCap":1688074514},{"date":"2024-10-04","current":-19.753355,"twenty":-43.367535,"median":-28.373476,"eighty":-20.209123,"marketCap":1640614867},{"date":"2024-10-11","current":-20.30237,"twenty":-43.311657,"median":-28.264591,"eighty":-20.195561,"marketCap":1686213351},{"date":"2024-10-18","current":-21.030656,"twenty":-43.248031,"median":-28.136018,"eighty":-20.195561,"marketCap":1746701137},{"date":"2024-10-25","current":-20.078282,"twenty":-43.248031,"median":-28.049113,"eighty":-20.145499,"marketCap":1667601725},{"date":"2024-10-31","current":-20.649706,"twenty":-43.248031,"median":-27.765641,"eighty":-20.132647,"marketCap":1715061372},{"date":"2024-11-08","current":-22.688907,"twenty":-43.252213,"median":-27.636067,"eighty":-20.132233,"marketCap":1884427173},{"date":"2024-11-15","current":-21.960621,"twenty":-43.252213,"median":-27.448241,"eighty":-20.132233,"marketCap":1823939387},{"date":"2024-11-22","current":-22.229527,"twenty":-43.231304,"median":-27.106738,"eighty":-20.132233,"marketCap":1846273338},{"date":"2024-11-29","current":-25.707412,"twenty":-43.145724,"median":-26.876224,"eighty":-20.132233,"marketCap":1914893729},{"date":"2024-12-06","current":-25.40483,"twenty":-43.145724,"median":-26.625426,"eighty":-20.132233,"marketCap":1892354961},{"date":"2024-12-13","current":-24.521289,"twenty":-43.145724,"median":-26.466422,"eighty":-20.132233,"marketCap":1826541758},{"date":"2024-12-20","current":-22.572657,"twenty":-43.145724,"median":-26.327469,"eighty":-20.132233,"marketCap":1681392092},{"date":"2024-12-27","current":-22.173248,"twenty":-43.145724,"median":-26.203648,"eighty":-20.132233,"marketCap":1651640919},{"date":"2025-01-03","current":-21.785943,"twenty":-43.145724,"median":-26.12294,"eighty":-20.132233,"marketCap":1622791296},{"date":"2025-01-10","current":-21.434947,"twenty":-43.151859,"median":-25.994723,"eighty":-20.130744,"marketCap":1596646325},{"date":"2025-01-17","current":-22.584761,"twenty":-43.151859,"median":-25.832017,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-24","current":-22.584761,"twenty":-43.151859,"median":-25.722549,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-31","current":-22.330591,"twenty":-43.151859,"median":-25.688138,"eighty":-20.130744,"marketCap":1663361078},{"date":"2025-02-07","current":-23.032583,"twenty":-43.151859,"median":-25.544418,"eighty":-20.130744,"marketCap":1715651020},{"date":"2025-02-14","current":-23.601438,"twenty":-43.151859,"median":-25.410136,"eighty":-20.130744,"marketCap":1758023904},{"date":"2025-02-21","current":-22.149042,"twenty":-43.151859,"median":-25.353801,"eighty":-20.130744,"marketCap":1649837817},{"date":"2025-02-28","current":-21.229191,"twenty":-43.151859,"median":-25.248903,"eighty":-20.130744,"marketCap":1581319962},{"date":"2025-03-07","current":-20.902402,"twenty":-43.157994,"median":-25.114351,"eighty":-20.129255,"marketCap":1556978093},{"date":"2025-03-14","current":-25.841364,"twenty":-43.157994,"median":-25.015259,"eighty":-20.118618,"marketCap":1407320673},{"date":"2025-03-21","current":-31.526661,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1716941957},{"date":"2025-03-28","current":-31.810986,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1732426315},{"date":"2025-04-04","current":-28.415807,"twenty":-43.157994,"median":-25.140052,"eighty":-20.118618,"marketCap":1547524873}],"updateTime":1743885402067}}}